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 Case series
 Patients: Female, 72-year-old • Female, 55-year-old • Female, 43-year-old
 Final Diagnosis: COVID provoked thromboembolism • COVID-19 • pulmonary embolism • rectus sheath hematoma
 Symptoms: Cough • fever • shortness of breath
 Medication: —
 Clinical Procedure: —
 Specialty: Critical Care Medicine • Diagnostics, Laboratory • Hematology • Infectious Diseases
 Objective: Unusual clinical course
 Background: The novel coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 
2 (SARS-CoV-2), often manifests a coagulopathy in severely ill patients, which may cause hemorrhage and/or 
thrombosis of varying severity. This report comprises the cases of 3 patients with COVID-19-associated coagu-
lopathy who were evaluated with thromboelastography (TEG) and activated partial thromboplastin time (aPTT) 
to enable personalized anticoagulant therapy.
 Case Reports: Three patients presented with COVID-19 pneumonia, confirmed by reverse transcription-polymerase chain re-
action, who developed thrombohemorrhagic coagulopathy. Case 1: A 72-year-old woman on long-term warfa-
rin therapy for a history of venous thromboembolism developed a right upper lobe pulmonary embolus, despite 
an international normalized ratio of 6.4 and aPTT of 120.7 s. TEG enabled successful anticoagulation with hepa-
rin, and her pulmonary infarct was no longer present 2 weeks later. Case 2: A 55-year-old woman developed a 
rectus sheath hematoma while on heparin, and TEG demonstrated increased fibrinolysis despite COVID-19 pa-
tients more commonly undergoing fibrinolytic shutdown. Case 3: A 43-year-old woman had significant throm-
bus burden while severely hypocoagulable according to laboratory testing. As the venous thrombi enlarged in 
a disseminated intravascular coagulopathic-like state, the heparin dose was escalated to achieve a target aPTT 
of 70 to 80 s, resulting in a flat line TEG tracing.
 Conclusions: These 3 cases of COVID-19 pneumonia with complex and varied clinical histories demonstrated the clinical val-
ue of TEG combined with the measurement of aPTT to facilitate personalized anticoagulation, resulting in good 
clinical outcomes.
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Background
Anticoagulant dosing in hospitalized patients infected with 
the severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2), the pathogen that causes the novel coronavirus dis-
ease 2019 (COVID-19), remains an area of controversy [1,2]. The 
United States’ National Institute of Health expert consensus on 
COVID-19 therapy currently cites insufficient data for or against 
the escalation of prophylactic anticoagulation to intermediate 
or therapeutic dosing for hospitalized patients without radio-
graphically proven macrothrombosis [1]. The initial enthusiasm 
for intermediate or therapeutic doses was based on the high 
rates of venous thromboembolisms (VTEs), pulmonary embo-
lisms (PEs), and arterial thromboses in patients with COVID-19, 
particularly those in the intensive care unit (ICU) [3,4]. Despite 
the known hypercoagulable states of these patients, bleed-
ing may occur with standard doses of low molecular weight 
heparin or unfractionated heparin (UFH) [5-8]. A major US tri-
al for therapeutic anticoagulation in critically ill patients with 
COVID-19 was recently halted owing to the high incidence of 
bleeding in patients in the ICU [9]. Providing the standard lev-
el of anticoagulation was an attractive therapeutic hypothesis, 
which was later shown to be potentially life-threatening [8,9].
The thrombohemorrhagic complications of COVID-19 ob-
served early in the pandemic prompted us to form a coagu-
lation committee tasked with adjudicating anticoagulation to 
simultaneously reduce the incidence of thrombosis and clinical-
ly significant hemorrhage. The viscoelastic hemostatic assays, 
thromboelastography (TEG) and rotational thromboelastom-
etry (ROTEM), are attractive tests for hemostatic monitoring 
because of their demonstrable use across several disciplines, 
including trauma resuscitation, extracorporeal membrane ox-
ygenation (ECMO), major surgery, obstetrics, and inherited 
and acquired coagulopathies [10-13]. Viscoelastic hemostatic 
assays have several advantages over the plasma-based com-
mon coagulation tests (eg, activated partial thromboplastin 
time (aPTT), prothrombin time). TEG/ROTEM enable the rap-
id identification of the specific disruption in the clotting pro-
cess, as well as fibrinolysis, and have proven to be cost-effec-
tive for improving patient outcomes [13,14]. TEG/ROTEM depict 
a graphical representation of the entire coagulation process 
using whole blood [12]. TEG parameters include the reaction 
time (R), which represents the time to initial fibrin formation 
(standard range, 5-10 min). Clot kinetics are represented by 
clot formation (K), which indicates the speed of fibrin build 
up (standard range, 1-3 min), and the alpha angle (a), which 
indicates the speed of clot strengthening (standard range, 
53-72°). Clot stability is represented by the maximum ampli-
tude (MA), which varies with the strength of the fibrin-plate-
let interaction (standard range, 50-70 mm). Lastly, lysis at 30 
min (LY30) represents fibrinolysis (standard range, 0-8%) [14].
TEG/ROTEM have demonstrated utility in small studies to identi-
fy coagulopathies and manage anticoagulation in patients with 
COVID-19 [15-19]. TEG was selected over ROTEM in our study 
because of the hospital laboratory’s preexisting familiarity in 
application to trauma and surgery. All 3 cases presented be-
low were confirmed positive for COVID-19 by reverse transcrip-
tase-polymerase chain reaction assay of nasopharyngeal swabs, 
based on the World Health Organization standard that targets 
the SARS-CoV-2 E gene and RdRp gene (BioFire Respiratory 2.1 
Panel, BioFire Diagnostics, Salt Lake City, UT, USA) [20,21]. Here, 
the utility of TEG (TEG 5000 analyzer with reagent kaolin and 
without heparinase, Haemonetics Corporation, Niles, IL, USA) 
as an adjunct to aPTT (Sysmex CA-1500 with reagents Innovin 
and CaCl2, Siemens Medical Solutions, Malvern, PA, USA) is dem-
onstrated for 3 patients hospitalized with COVID-19-associated 
coagulopathy to enable personalized anticoagulant therapy. The 
patients’ demographic data are shown in Table 1.
Patient 1 Patient 2 Patient 3
Demographics
 Age (years) 72 55 43
 Sex Female Female Female
 BMI (kg/m2) 32.3 40.6 37.0
Comorbidities
 Type II diabetes mellitus Yes Yes No
 Hypertension No Yes No
 Cardiovascular disease No No No
 Chronic renal failure Yes No No
 Immunosuppression No No No
Table 1. Patient demographics for the 3 cases.
BMI – body mass index.
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Case Reports
Case 1
A 72-year-old woman on long-term warfarin therapy for a his-
tory of VTEs presented with COVID-19 pneumonia. Three days 
after admission, she was diagnosed with a right upper lobe PE, 
despite an international normalized ratio (INR) of 6.4 and aPTT 
of 120.7 s (reference range, 23.0-34.0 s) (Figure 1B). Intravenous 
(IV) UFH of 8 units/kg/h was started. Doppler ultrasound of the 
upper and lower extremities did not reveal a deep vein thrombus 
(DVT). The following day, TEG demonstrated severe hypocoagu-
lability (Figure 1A). The UFH dosage was decreased to 3 units/
kg/h. For the next 2 weeks, TEG enabled goal-directed therapy 
with small doses of UFH from 3 to 5 units/kg/h, the goal being 
maintenance of the TEG parameter R of 12 to 17 min and aPTT 
of 50 to 60 s. It took the duration of these 2 weeks for the INR 
to decrease to subtherapeutic levels. The patient’s right upper 
lobe pulmonary infarct was no longer present on repeat imag-
ing 14 days after its discovery (Figure 1C). On the same day as 
repeat imaging, TEG demonstrated normal hemostasis, and her 
aPTT was 25.0 s (Figure 1A). The patient was placed on apixa-
ban 5 mg twice daily. In this case, there was no attempt to di-
agnose lupus anticoagulant or acquired hemophilia A because 
the severe prolongation of aPTT returned to normal 3 days after 
withholding warfarin therapy. Subsequently, heparin was used 
to provide anticoagulant therapy guided by TEG.
Case 2
A 55-year-old woman with moderately severe COVID-19 pneu-
monia was placed on therapeutic anticoagulation with 100 mg 
Figure 1.  Case 1: A 72-year-old woman with a past history of venous thromboembolism on chronic warfarin therapy presented 
with COVID-19 pneumonia. Three days after admission, she developed a pulmonary embolus despite an international 
normalized ratio of 6.4. (A) The patient’s initial thromboelastographic (TEG) tracing demonstrated hypocoagulopathy 1 day 
after developing the pulmonary embolus (dashed line). Two weeks later, her TEG tracing demonstrated hemostasis (dotted 
line). (B) Computed tomography angiogram of the chest in coronal view depicting branching filling defect along the distal 
right main pulmonary artery extending into the right upper lobe segmental branches (yellow arrow). (C) Right upper lobe 
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subcutaneous (SQ) enoxaparin every 12 h upon admission to 
the ICU for worsening respiratory insufficiency. Two days after 
admission, she developed a spontaneous rectus sheath hema-
toma, and the enoxaparin was held (Figure 2B). Four days after 
admission, TEG and aPTT demonstrated hypercoagulability, and 
she was restarted on anticoagulants. IV UFH was chosen over 
enoxaparin to prevent SQ administration in the abdomen where 
the rectus sheath hematoma was present. In addition, anti-factor 
Xa levels were not accessible to monitor enoxaparin. A Doppler 
ultrasound of the patient’s extremities was negative for DVT. For 
the next 8 days, UFH dosing from 8 to 12 units/kg/h was guid-
ed by the TEG to maintain a target aPTT of 40 to 50 s. Twelve 
days after admission, TEG revealed a LY30 of 28.5%, indicating 
fibrinolysis (Figure 2A). Concern for an expanding hematoma 
prompted a decrease in the UFH dosage from 8 to 7 units/kg/h. 
Fifteen days after admission, repeat imaging of the abdomen 
revealed a marginal decrease in size of the rectus sheath he-
matoma (Figure 2C). For the next 4 days, the patient was main-
tained on 7 units/kg/h of IV UFH. Seventeen days after admis-
sion, her treatment with IV heparin was stopped in preparation 
for discharge, and TEG demonstrated hemostasis (Figure 2A).
Case 3
A 43-year-old woman with no past medical history was trans-
ferred with moderately severe COVID-19 pneumonia, hypoxia, 
Figure 2.  Case 2: A 55-year-old woman admitted with COVID-19 pneumonia was placed on therapeutic anticoagulation with 100 mg 
subcutaneous enoxaparin every 12 h upon admission. Two days after admission, she developed a spontaneous rectus sheath 
hematoma and enoxaparin was held. (A) Twelve days after admission, thromboelastography (TEG) revealed fibrinolysis 
(dashed line). Five days later, her TEG tracing demonstrated hemostasis (dotted line). (B) Two days after admission, 
computed tomography of the abdomen and pelvis showed a large intramuscular hematoma involving the right rectus 
abdominus muscle measuring 12.8×6.8 cm in axial view. (C) Computed tomography 2 weeks later revealed a slightly smaller 
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bilateral edema of the lower extremities, bilateral submassive 
pulmonary emboli, and acute-onset idiopathic thrombocytope-
nic purpura, diagnosed serologically. A Doppler ultrasound of all 
4 extremities revealed a right popliteal DVT. She had a platelet 
count of 37×109/L (reference range, 130-470×109/L) and fibrin-
ogen level of 137 mg/dL (reference range, 180-350 mg/dL) on 
admission. In addition, her D-dimer level was beyond the up-
per limit of the laboratory measurement of 35.2 mg/L (refer-
ence range, <0.53 mg/L). She was administered fibrinogen con-
centrate and platelets periodically to maintain a platelet count 
>50×109/L and fibrinogen >150 mg/dL. She also received a dose 
of romiplostim (Nplate) to stimulate thrombopoiesis. Subsequent 
testing for heparin-induced thrombocytopenia by serotonin 
release assay and platelet-Factor 4 antibody serology was neg-
ative. For the next 7 days, owing to concern for thrombocyto-
penia, hypofibrinogenemia, and an elevated D-dimer level, she 
was administered IV UFH doses of 15 to 20 units/kg/h to initial-
ly maintain a goal aPTT of 40 to 50 s. The goal was to prevent 
hemorrhagic manifestation of the thrombohemorrhagic pheno-
type while simultaneously escalating anticoagulation therapy. 
Seven days after admission, computed tomography revealed 
the development of renal vein thrombosis, inferior vena cava 
thrombosis, and right external and internal iliac thromboses, 
despite high dose anticoagulation (Figure 3B). With significant 
thrombus burden, a higher aPTT goal of 60 to 70 s was target-
ed, despite a TEG tracing that was nearly a flat line (Figure 3A). 
Figure 3.  Case 3: A 43-year-old woman with no past medical history was admitted with COVID-19 pneumonia, bilateral pulmonary 
emboli, and acute-onset idiopathic thrombocytopenic purpura. (A) Seven days after admission, the patient developed 
thrombi despite thromboelastography (TEG) depicting a nearly flat line tracing (dashed line). Two weeks later, the 
anticoagulant dose was increased after enlargement of venous thrombi, pushing her TEG tracing to a complete flat line (solid 
line). (B) Seven days after admission, computed tomography of the abdomen and pelvis in coronal view showed thrombosis 
within the entirety of the left renal vein and the inferior vena cava, both above and below the level of the renal veins. 

























Bunch C.M. et al: 
COVID-19 and TEG
© Am J Case Rep, 2021; 22: e931080
e931080-5 Indexed in: [PMC] [PubMed] [Emerging Sources Citation Index (ESCI)][Web of Science by Clarivate]
This work is licensed under Creative Common Attribution-
NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
Repeat abdominal imaging conducted 18 days after admission 
revealed enlargement of venous thrombi (Figure 3C). A decision 
was made to further increase the dosage of UFH to achieve a 
target aPTT of 70 to 80 s, resulting in a severely hypocoagulo-
pathic TEG showing a complete flat line (Figure 3A). After this 
final escalation of UFH, a gradual reduction of the D-dimer level 
and increase in fibrinogen occurred under this regimen for the 
next 10 days. The patient’s hypoxia, dyspnea, and lower limb 
edema resolved prior to discharge. Repeat imaging to demon-
strate clot resolution prior to discharge was not obtained be-
cause the patient was asymptomatic, and the family request-
ed no further testing owing to finances. Subsequent follow-up 
revealed that the patient had returned to normal occupational 
function and had no residual pulmonary or vascular symptoms.
Discussion
These 3 cases demonstrate the utility of TEG in guiding anti-
coagulation therapy for complex and coagulopathic critically ill 
patients with COVID-19 in the ICU. Case 1 represents the util-
ity of TEG to guide heparin in a patient where a warfarin-in-
duced INR of 6.4 did not prevent the development of a PE as-
sociated with COVID-19 pneumonia. Low doses of UFH were 
administered with the notion that the anti-inflammatory and 
antiviral effects of UFH would assist in preventing further ex-
pansion of the thrombus in the lung [22]. The pulmonary ‘em-
bolus’ in this case may be a misnomer since the patient had 
no VTE on 4-extremity ultrasound. Rather, this was likely a 
pulmonary immunothrombus caused by the local endothelial 
inflammation in the pulmonary vasculature [2,6,23]. The res-
olution of the soft clot after 2 weeks of UFH therapy may not 
only have been due to the direct anticoagulation, but also in-
directly due to the anti-inflammatory and antiviral effects of 
the heparin molecule at the endothelial surface [22].
In Case 2, TEG unveiled fibrinolysis otherwise undetectable by 
common coagulation tests, enabling the personalized adjust-
ment of anticoagulation. It is uncertain whether the excessive 
fibrinolysis was causative of the hematoma or was a second-
ary response to the presence of the hematoma. Severely ill pa-
tients with COVID-19 more commonly demonstrate fibrinolytic 
shutdown, so this TEG pattern should prompt a search for an 
occult hemorrhage such as in this patient [15,19,24]. Finally, 
Case 3 demonstrates the immunothrombotic phenotype com-
mon in critically ill patients with COVID-19, who may clot de-
spite therapeutic levels of anticoagulation [2,6,7]. Informed by 
the patient’s clinical state and assisted by TEG, the aPTT goal 
was escalated gradually for this patient with significant throm-
bus burden, which resulted in complete recovery.
The COVID-19 coagulopathy is dependent on the unique im-
munothrombotic changes that occur at the endothelium, which 
can cause an endotheliitis [23]. Although this more selectively 
involves the lung, it can potentially involve any vascular tissue. 
As there is infiltration of monocytes and macrophages into in-
volved sites, an acute inflammatory response is induced with 
elevated levels of proinflammatory cytokines such as inter-
leukin (IL)-6, IL-1, tumor necrosis factor a, and IL-8 [25,26]. In 
severe cases, the response is to a degree that is described as 
a “cytokine storm”. These inflammatory cytokines in turn ac-
tivate the intrinsic pathway of the coagulation cascade, with 
factor XII activation and progression to thrombin generation. 
Fibrinolysis is also impaired with upregulation of plasminogen 
activator inhibitor 1 expression [27].
The effect of this cytokine storm on the endothelial surface may 
cause a pathophysiologic milieu like that found in patients on 
ECMO, as well as in patients who are post-resuscitative and 
recovering from trauma [11,28]. The persistence of fibrinolytic 
shutdown in all patients with COVID-19, regardless of whether 
the patient bled, reflects one of the interesting pathophysio-
logic moments that defines the hypercoagulopathy of this nov-
el disease [19,24]. The intensity of required anticoagulation in 
these patients may be a function of the intensity of inflamma-
tion caused by the cytokine storm. As the storm abates, so too 
does the requirement of higher levels of anticoagulation, sug-
gesting the need for intense hemostatic monitoring not just 
with the aPTT, but also with adjunctive TEG analysis. We have 
drawn from the experience of ECMO, whereby frequent mon-
itoring by a specialized coagulation team follows the clinical 
pattern of aPTT, anti-factor Xa levels, and TEG to guide anti-
coagulation therapy [11]. For patients with COVID-19, we uti-
lized the same strategy by following biochemical inflammatory 
markers, D-dimer, fibrinogen, aPTT, and TEG to guide antico-
agulation. Notably, we were unable to use anti-factor Xa lev-
els owing to limitations at our institution, but in an ideal sit-
uation anti-factor Xa levels would also be used to adjudicate 
UFH therapy. We have found this strategy helpful for our pa-
tients, as demonstrated by the 3 examples described above 
of goal-directed and personalized anticoagulation for patients 
with COVID-19-induced coagulopathy.
Conclusions
These 3 cases of COVID-19 pneumonia with complex and var-
ied clinical histories demonstrated the value of using TEG 
combined with the measurement of aPTT to facilitate individ-
ualized anticoagulation, resulting in good clinical outcomes.
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